NCT05160649|Unknown
Effect of Covid 19 Infection on Fetomaternal Outcome
Effect of Time of COVID 19 Infection on Fetomaternal Outcome, and Immunological Changes During the Disease Course
Loading search results
Effect of Time of COVID 19 Infection on Fetomaternal Outcome, and Immunological Changes During the Disease Course
Sponsor study identifier
observational
50
1 country
1
Study Start
October 10, 2021
Actual (reported)Primary Completion
June 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was discovered for the first time in December 2019 in Wuhan (China) and the disease it causes is called coronavirus disease 2019 (COVID-19). Now, this pandemic is rapidly spreading all over the world. Pregnant have higher rates of COVID-19, associated with hospitalizations, and severe in-hospital outcomes. Immune responses may have a potential role in the diagnosis, treatment, and prognosis of patients with COVID-19. So we need of identifying biomarkers for disease severity and progression.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
October 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
October 10, 2021
Actual (reported)December 15, 2021
Actual (reported)December 16, 2021
Actual (reported)June 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
October 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
First, second and third trimester fetomaternal complications.
Abdominal examination: to detect any abnormality as intra uterine growth restriction, with serial ultrasound estimation.
3 months
fetal distress
Intrapartum fetal heart rate (FHR) to detect viability and any abnormalities. Pregnant women diagnosed to have intrapartum fetal distress (Non reassuring or pathological changes according to NICE guidelines 2017)
3 months
fetal outcome
3 months
A prospective observational study
Fayoum university
Al Fayyum, 63514, Egypt
Laila E Abdelfattah, Ass. prof
Associated professor of obestatrics and gynecology Faculty of medicine Fayoume university
Eman E Mahmoud, lecturer
Lecturer of clinical and chemical pathology
First Submitted
December 15, 2021
First Posted
December 16, 2021
Study Start
October 10, 2021
Actual (reported)Primary Completion
June 2023
Estimated (date passed)Mesenchymal Stromal Cells for the Treatment of Patients With COVID-19.
Time of infection and fetal complications
3 months
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
October 2023
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
April 28, 2023
Record last verified: 2023-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: